17
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T0707L | Cyclophosphamide | DNA Alkylator/Crosslinker , DNA , MRP | |
Cyclophosphamide is an alkylating agent used in the treatment of several forms of cancer including leukemias, lymphomas and breast cancer. | |||
T0707 | Cyclophosphamide hydrate | Cyclophosphamide monohydrate | DNA Alkylator/Crosslinker , DNA , MRP |
Cyclophosphamide hydrate is a DNA alkylating agent, an inhibitor of DNA synthesis. Cyclophosphamide hydrate has antitumor and immunosuppressive activities. | |||
T35643 | 4-hydroperoxy Cyclophosphamide | 4-hydroperoxy Cyclophosphamide,4-OOH-CY | |
4-hydroperoxy Cyclophosphamide (4-OOH-CY) is the active metabolite form of the prodrug Cyclophosphamide. 4-OOH-CY crosslinks DNA and induces T cell apoptosis independent of death receptor activation, but activates mitoch... | |||
T35645 | 4-oxo Cyclophosphamide | ||
4-oxo Cyclophosphamide is an inactive metabolite of the alkylating agent cyclophosphamide .1,2It is formed from cyclophosphamide through a 4-hydroxycyclophosphamide intermediate by aldehyde dehydrogenases.2 1.Struck, R.F... | |||
T1414 | Sodium 2-mercaptoethanesulfonate | Mitexan,Uromitexan,Mesna,Mesnum,Mesnex | Others |
Sodium 2-mercaptoethanesulfonate (Uromitexan) is a sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from antineoplastic agents, such as ifosfamide or cyclophosphamide. | |||
T38410 | Phosphoramide mustard | DNA Alkylation , Drug Metabolite | |
Phosphoramide mustard is a toxic metabolite of cyclophosphamide with anticancer activity and ovarian toxicity that induces DNA damage. | |||
T1055 | Ifosfamide | NSC109724,Isophosphamide | DNA Alkylator/Crosslinker , DNA/RNA Synthesis |
Ifosfamide (NSC-109724) alkylates and forms DNA crosslinks, thereby preventing DNA strand separation and DNA replication. Ifosfamide is a synthetic analog of the nitrogen mustard cyclophosphamide with antineoplastic acti... | |||
T29845 | Alcophosphamide | NSC 153182,Hydroxyphosphamide | |
Alcophosphamide is a urinary metabolite of cyclophosphamide which may be used in proteomics research. | |||
T37108 | Carboxyphosphamide | ||
Carboxyphosphamide is an inactive metabolite of the alkylating agent cyclophosphamide .1It is formed from cyclophosphamideviaoxidation of the intermediate metabolite aldophosphamide by aldehyde dehydrogenase. 1.Manthey, ... | |||
T68592 | Mafosfamide sodium | ||
Mafosfamide sodium is an oxazaphosphorine derivative with antineoplastic properties. It alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis. | |||
T24102 | GR-203040 HCl | GR 203040,GR-203040 hydrochloride,GR-203040,GR203040 | |
GR203040 inhibits cyclophosphamide-induced damage in the rat and ferret bladder. GR-203040 is a selective NK1 receptor antagonist. | |||
T68434 | Mafosfamide | ||
Mafosfamide is a synthetic oxazaphosphorine derivative with antineoplastic properties. It alkylates DNA, forming DNA cross-links and inhibiting DNA synthesis. | |||
T25723 | L-Ifosfamide | (+)-Ifosfamide | |
L-Ifosfamide is nitrogen mustard, a chemotherapeutic antineoplastic, and more precisely an alkylating agent structural analog of cyclophosphamide with respect to which presents some differences regard to the antitumor ac... | |||
T36701 | Phosphoramide mustard (cyclohexanamine) | ||
Phosphoramide mustard cyclohexanamine is the major metabolite for Cyclophosphamide , with anticancer activitiy. Phosphoramide mustard cyclohexanamine induces DNA adduct formation in ovarian granulosa cells, induces DNA d... | |||
T70304 | CI-898 HCl | ||
CI-898 HCl is a lipophilic antifolate inhibitor of dihydrofolate reductase (DHFR). It has enhanced binding to DHFR in the presence of the cofactor NADPH. Cl-898 HCl inhibits cell growth and halts the cell cycle at the G1... | |||
T63464 | ERCC1-XPF-IN-1 | ||
ERCC1-XPF-IN-1 is a potent, high-affinity inhibitor of ERCC1-XPF (IC50: 0.49 μM). ERCC1-XPF-IN-1 inhibits the removal of CPDs, reduces the toxicity of cyclophosphamide to colorectal cancer cells, enhances the cytotoxic e... | |||
T71549 | RKS-262 | ||
RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line as... |